Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma

Nature Reviews Cancer

Volumn 14, Issue 10, 2014, Pages 651-661

  Jones, Chris ^a   Baker, Suzanne J ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN RECEPTOR 1; HISTONE;

BRAIN CORTEX; BRAIN STEM; CARCINOGENESIS; CHILD; CHILDHOOD DISEASE; CHROMATIN; DIFFUSE HIGH GRADE GLIOMA; EPIGENETICS; GENETIC REGULATION; GLIOMA; GROUPS BY AGE; HUMAN; PILOCYTIC ASTROCYTOMA; PONTINE GLIOMA; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL TIME;

EID: 84930188532     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3811     Document Type: Review

References (99)

1. Ostrom, Q. T. et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol. 15 (Suppl 2), ii1-ii56 (2013
2. Jones, C., Perryman, L., & Hargrave, D. Paediatric and adult malignant glioma: close relatives or distant cousins? Nature Rev. Clin. Oncol. 9, 400-413 (2012
3. Kramm, C. M. et al. Thalamic high-grade gliomas in children: a distinct clinical subset? Neuro Oncol. 13, 680-689 (2011
4. Wolff, B. et al. Pediatric high grade glioma of the spinal cord: results of the HIT-GBM database. J. Neurooncol. 107, 139-146 (2012
5. Karremann, M. et al. Cerebellar location may predict an unfavourable prognosis in paediatric high-grade glioma. Br. J. Cancer 109, 844-851 (2013
6. Warren, K. E. Diffuse intrinsic pontine glioma: poised for progress. Front. Oncol. 2, 205 (2012
7. Hargrave, D., Bartels, U., & Bouffet, E. Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol. 7, 241-248 (2006
8. Roujeau, T. et al. Stereotactic biopsy of diffuse pontine lesions in children. J. Neurosurg. 107, 1-4 (2007
9. Broniscer, A. et al. Prospective collection of tissue samples at autopsy in children with diffuse intrinsic pontine glioma. Cancer 116, 4632-4637 (2010
10. Angelini, P., Hawkins, C., Laperriere, N., Bouffet, E., & Bartels, U. Post mortem examinations in diffuse intrinsic pontine glioma: challenges and chances. J. Neurooncol. 101, 75-81 (2011). References 9 and 10 report the feasibility of collecting DIPG tissue and autopsy and the quality of nucleic acids from autopsy samples for research.
11. Monje, M. et al. Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma. Proc. Natl Acad. Sci. USA 108, 4453-4458 (2011
12. Qaddoumi, I., Sultan, I., & Gajjar, A. Outcome and prognostic features in pediatric gliomas: a review of 6212 cases from the Surveillance, Epidemiology, and End Results database. Cancer 115, 5761-5770 (2009
13. WHO Classification of Tumours of the Central Nervous System (eds Louis, D. N., Ohgaki, H., Wiestler, O. D., & Cavenee, W. K.) (World Health Organisation, 2007
14. Phillips, H. S. et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9, 157-173 (2006
15. Paugh, B. S. et al. Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J. Clin. Oncol. 29, 3999-4006 (2011
16. Paugh, B. S. et al. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J. Clin. Oncol. 28, 3061-3068 (2010
17. Bjerke, L. et al. Histone H3.3 mutations drive pediatric glioblastoma through upregulation of MYCN. Cancer Discov. 3, 512-519 (2013
18. Sturm, D. et al. Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nature Rev. Cancer 14, 92-107 (2014
19. Buczkowicz, P. et al. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nature Genet. 46, 451-456 (2014
20. Fontebasso, A. M. et al. Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nature Genet. 46, 462-466 (2014
21. Taylor, K. R. et al. Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nature Genet. 46, 457-461 (2014
22. Wu, G. et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nature Genet. 46, 444-450 (2014). References 19-22 reported recurrent mutations in ACVR1, exclusively in DIPG, and they provided genome-wide data to define the somatic mutation landscape of DIPG. Reference 22 also identified NTRK fusion genes in infant gliomas, and germline mutations in DNA mismatch repair genes in paediatric HGGs with minimal CNAs.
23. Schwartzentruber, J. et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482, 226-231 (2012
24. Bax, D. A. et al. A distinct spectrum of copy number aberrations in pediatric high-grade gliomas. Clin. Cancer Res. 16, 3368-3377 (2010
25. Puget, S. et al. Mesenchymal transition and PDGFRA amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas. PLoS ONE 7, e30313 (2012
26. Qu, H. Q. et al. Genome-wide profiling using single-nucleotide polymorphism arrays identifies novel chromosomal imbalances in pediatric glioblastomas. Neuro Oncol. 12, 153-163 (2010
27. Zarghooni, M. et al. Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor ? and poly (ADP-ribose) polymerase as potential therapeutic targets. J. Clin. Oncol. 28, 1337-1344 (2010
28. Barrow, J. et al. Homozygous loss of ADAM3A revealed by genome-wide analysis of pediatric high-grade glioma and diffuse intrinsic pontine gliomas. Neuro Oncol. 13, 212-222 (2011
29. Kyritsis, A. P., Bondy, M. L., Rao, J. S., & Sioka, C. Inherited predisposition to glioma. Neuro Oncol. 12, 104-113 (2010
30. Eguchi, M. et al. Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25). Blood 93, 1355-1363 (1999
31. Lannon, C. L., & Sorensen, P. H. ETV6-NTRK3: a chimeric protein tyrosine kinase with transformation activity in multiple cell lineages. Semin. Cancer Biol. 15, 215-223 (2005
32. Li, Z. et al. ETV6-NTRK3 fusion oncogene initiates breast cancer from committed mammary progenitors via activation of AP1 complex. Cancer Cell 12, 542-558 (2007
33. Knezevich, S. R. et al. ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma. Cancer Res. 58, 5046-5048 (1998
34. Butti, M. G. et al. A sequence analysis of the genomic regions involved in the rearrangements between TPM3 and NTRK1 genes producing TRK oncogenes in papillary thyroid carcinomas. Genomics 28, 15-24 (1995
35. Zhang, J. et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nature Genet. 45, 602-612 (2013
36. Jones, D. T. et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nature Genet. 45, 927-932 (2013
37. Frattini, V. et al. The integrated landscape of driver genomic alterations in glioblastoma. Nature Genet. 45, 1141-1149 (2013
38. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008
39. Parsons, D. W. et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807-1812 (2008). References 38 and 39 are the first reports of the almost universal involvement of mutations in the RTK-RAS-PI3K, p53 and RB signalling pathways in adult glioblastoma. Reference 38 used selective sequencing of candidate genes. Reference 39 was the first whole-exome analysis of glioblastoma, and identified IDH1 mutations, thus providing molecular evidence for distinct aetiologies between primary and secondary glioblastomas.
40. Schiffman, J. D. et al. Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res. 70, 512-519 (2010
41. Nicolaides, T. P. et al. Targeted therapy for BRAFV600E malignant astrocytoma. Clin. Cancer Res. 17, 7595-7604 (2011
42. Bautista, F. et al. Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas. Pediatr. Blood Cancer 61, 1101-1103 (2014
43. Huillard, E. et al. Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. Proc. Natl Acad. Sci. USA 109, 8710-8715 (2012
44. Schindler, G. et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 121, 397-405 (2011
45. Paugh, B. S. et al. Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas. Cancer Res. 73, 6219-6229 (2013
46. Snuderl, M. et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 20, 810-817 (2011
47. Szerlip, N. J. et al. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc. Natl Acad. Sci. USA 109, 3041-3046 (2012
48. Little, S. E. et al. Receptor tyrosine kinase genes amplified in glioblastoma exhibit a mutual exclusivity in variable proportions reflective of individual tumor heterogeneity. Cancer Res. 72, 1614-1620 (2012
49. Barton, K. L. et al. PD-0332991, a CDK4/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem glioma. PLoS ONE 8, e77639 (2013
50. Wu, G. et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nature Genet. 44, 251-253 (2012). References 23 and 50 report the co-discovery of the first histone mutations in human cancer, and the identification of histone H3 mutations in paediatric glioblastoma. Reference 50 was the first to report histone H3 mutations in DIPG, with the frequency of mutation providing strong evidence for distinct pathogenesis of DIPG.
51. Yuen, B. T., & Knoepfler, P. S. Histone h3.3 mutations: a variant path to cancer. Cancer Cell 24, 567-574 (2013
52. Maze, I., Noh, K. M., Soshnev, A. A., & Allis, C. D. Every amino acid matters: essential contributions of histone variants to mammalian development and disease. Nature Rev. Genet. 15, 259-271 (2014
53. Elsaesser, S. J., Goldberg, A. D., & Allis, C. D. New functions for an old variant: no substitute for histone H3.3. Curr. Opin. Genet. Dev. 20, 110-117 (2010
54. Skene, P. J., & Henikoff, S. Histone variants in pluripotency and disease. Development 140, 2513-2524 (2013
55. Khuong-Quang, D. A. et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol. 124, 439-447 (2012
56. Sturm, D. et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22, 425-437 (2012
57. Fontebasso, A. M. et al. Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. Acta Neuropathol. 125, 659-669 (2013
58. Aihara, K. et al. H3F3A K27M mutations in thalamic gliomas from young adult patients. Neuro Oncol. 16, 140-146 (2014
59. Broniscer, A. et al. Clinical and molecular characteristics of malignant transformation of low-grade glioma in children. J. Clin. Oncol. 25, 682-689 (2007
60. Cantone, I., & Fisher, A. G. Epigenetic programming and reprogramming during development. Nature Struct. Mol. Biol. 20, 282-289 (2013
61. Li, M., Liu, G. H., & Izpisua Belmonte, J. C. Navigating the epigenetic landscape of pluripotent stem cells. Nature Rev. Mol. Cell Biol. 13, 524-535 (2012
62. Hirabayashi, Y., & Gotoh, Y. Epigenetic control of neural precursor cell fate during development. Nature Rev. Neurosci. 11, 377-388 (2010
63. Jenuwein, T., & Allis, C. D. Translating the histone code. Science 293, 1074-1080 (2001
64. Plass, C. et al. Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nature Rev. Genet. 14, 765-780 (2013
65. Margueron, R., & Reinberg, D. The Polycomb complex PRC2 and its mark in life. Nature 469, 343-349 (2011
66. Lewis, P. W. et al. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 340, 857-861 (2013
67. Venneti, S. et al. Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of Zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas. Brain Pathol. 23, 558-564 (2013
68. Bender, S. et al. Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer Cell 24, 660-672 (2013
69. Chan, K. M. et al. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev. 27, 985-990 (2013
70. Wagner, E. J., & Carpenter, P. B. Understanding the language of Lys36 methylation at histone H3. Nature Rev. Mol. Cell Biol. 13, 115-126 (2012
71. Swartling, F. J. et al. Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. Cancer Cell 21, 601-613 (2012
72. Barone, G., Anderson, J., Pearson, A. D., Petrie, K., & Chesler, L. New strategies in neuroblastoma: therapeutic targeting of MYCN and ALK. Clin. Cancer Res. 19, 5814-5821 (2013
73. Di Lorenzo, A., & Bedford, M. T. Histone arginine methylation. FEBS Lett. 585, 2024-2031 (2011
74. Behjati, S. et al. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nature Genet. 45, 1479-1482 (2013
75. Johnson, R. A. et al. Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature 466, 632-636 (2010
76. Gibson, P. et al. Subtypes of medulloblastoma have distinct developmental origins. Nature 468, 1095-1099 (2010
77. Szenker, E., Ray-Gallet, D., & Almouzni, G. The double face of the histone variant H3.3. Cell Res. 21, 421-434 (2011
78. Killela, P. J. et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc. Natl Acad. Sci. USA 110, 6021-6026 (2013
79. Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765-773 (2009
80. Brennan, C. W. et al. The somatic genomic landscape of glioblastoma. Cell 155, 462-477 (2013
81. Hojfeldt, J. W., Agger, K., & Helin, K. Histone lysine demethylases as targets for anticancer therapy. Nature Rev. Drug Discov. 12, 917-930 (2013
82. Shore, E. M. et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nature Genet. 38, 525-527 (2006
83. Kaplan, F. S., Lounev, V. Y., Wang, H., Pignolo, R. J., & Shore, E. M. Fibrodysplasia ossificans progressiva: a blueprint for metamorphosis. Ann. NY Acad. Sci. 1237, 5-10 (2011
84. Chaikuad, A. et al. Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva. J. Biol. Chem. 287, 36990-36998 (2012
85. Bagarova, J. et al. Constitutively active ALK2 receptor mutants require type II receptor cooperation. Mol. Cell. Biol. 33, 2413-2424 (2013
86. Shen, Q. et al. The fibrodysplasia ossificans progressiva R206H ACVR1 mutation activates BMP-independent chondrogenesis and zebrafish embryo ventralization. J. Clin. Invest. 119, 3462-3472 (2009
87. Gomes, W. A., Mehler, M. F., & Kessler, J. A. Transgenic overexpression of BMP4 increases astroglial and decreases oligodendroglial lineage commitment. Dev. Biol. 255, 164-177 (2003
88. Kan, L. et al. Substance P signaling mediates BMP-dependent heterotopic ossification. J. Cell Biochem. 112, 2759-2772 (2011
89. Lee, J. et al. Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell 13, 69-80 (2008
90. Piccirillo, S. G. et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 444, 761-765 (2006
91. Zhao, H., Ayrault, O., Zindy, F., Kim, J. H., & Roussel, M. F. Post-transcriptional down-regulation of Atoh1/Math1 by bone morphogenic proteins suppresses medulloblastoma development. Genes Dev. 22, 722-727 (2008
92. Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546-1558 (2013
93. Ballester, L. Y. et al. Morphologic characteristics and immunohistochemical profile of diffuse intrinsic pontine gliomas. Am. J. Surg. Pathol. 37, 1357-1364 (2013
94. Schumacher, M., Schulte-Monting, J., Stoeter, P., Warmuth-Metz, M., & Solymosi, L. Magnetic resonance imaging compared with biopsy in the diagnosis of brainstem diseases of childhood: a multicenter review. J. Neurosurg. 106, 111-119 (2007
95. Albright, A. L. et al. Magnetic resonance scans should replace biopsies for the diagnosis of diffuse brain stem gliomas: a report from the Children's Cancer Group. Neurosurgery 33, 1026-1030 (1993
96. Baker, J. N. et al. Bereaved parents' intentions and suggestions about research autopsies in children with lethal brain tumors. J. Pediatr. 163, 581-586 (2013
97. Geoerger, B. et al. Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro Oncol. 13, 109-118 (2011
98. Walker, D. A. et al. A multi-disciplinary consensus statement concerning surgical approaches to low-grade, high-grade astrocytomas and diffuse intrinsic pontine gliomas in childhood (CPN Paris 2011) using the Delphi method. Neuro Oncol. 15, 462-468 (2013
99. Chalhoub, N., & Baker, S. J. PTEN and the PI3-kinase pathway in cancer. Annu. Rev. Pathol. 4, 127-150 (2009).